With more than half a million new cases each year, hepatocellular carcinoma (HCC) is the
fifth most common tumor worldwide and the third cause of cancer-related deaths [1]. At the …

Hepatocellular carcinoma is a common malignancy affecting approximately one million
people around the world every year. The incidence is low in the occidental world and high in …

Tumor-initiating cells (T-ICs) are a subpopulation of chemoresistant tumor cells that have
been shown to cause tumor recurrence upon chemotherapy. Identification of T-ICs and their …

Purpose: ART and its derivatives, clinically used antimalarial agents, have recently shown
antitumor activities. However, the mechanisms underlying these activities remain unclear …

This study is to investigate the molecular mechanism of radiation-enhanced cell
invasiveness of hepatocellular carcinoma (HCC) correlating with clinical patients …

The poor prognosis of hepatocellular carcinoma (HCC) has been associated with
recurrence and metastasis. Recently, we established a pair of HCC cell lines from a primary …

Written by world-class experts in clinical cancer therapeutics, Physicians' Cancer
Chemotherapy Drug Manual 2017 provides a complete, easy-to-use catalog of over 100 …

Tumor-initiating cell (TIC) is a subpopulation of cells in tumors that are responsible for tumor
initiation and progression. Recent studies indicate that hepatocellular carcinoma-initiating …

Techniques to improve the accumulation of therapeutic agents in tumors, which
subsequently enhance the therapeutic efficacy of anticancer drugs against malignant tumors …

Written by world-class experts in clinical cancer therapeutics, Physicians' Cancer
Chemotherapy Drug Manual 2020 provides a complete, easy-to-use catalog of over 100 …